No Data
No Data
TD Cowen Maintains Crinetics(CRNX.US) With Buy Rating
TD Cowen Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)
Crinetics Pharmaceuticals Q4 Net Loss Narrows
Express News | Crinetics Pharmaceuticals Inc: For 2025, We Anticipate Our Cash Used in Operations to Be Between $340 and $380 Mln
Crinetics | 10-K: Annual report
Crinetics | 8-K: Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update